<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700177</url>
  </required_header>
  <id_info>
    <org_study_id>12345</org_study_id>
    <nct_id>NCT03700177</nct_id>
  </id_info>
  <brief_title>Ropivacaine 0,2% Plus Dexamethasone Versus Ropivacaine 0,2% Plus Placebo in Modified Pectoral Block</brief_title>
  <official_title>Ropivacaine 0,2% Plus Dexamethasone Versus Ropivacaine 0,2% Plus Placebo in Modified Pectoral Block - a Randomized, Double-blind, Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find out if dexamethasone used as adjuvant to ropivacaine, a long-lasting local
      anesthetic, prolongs the duration of modified pectoral nerve block in women undergoing breast
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast surgeries are one of the most common forms of surgery conducted in hospitals, and even
      relatively minor interventions can be associated with significant postoperative pain. The
      most common surgical procedure for breast cancer is modified radical mastectomy, which means
      removing a generous amount of skin and the entire breast with axillary evacuation. According
      to the literature, up to 50% of breast surgery patients experience severe acute postoperative
      pain, with 10-40% breast cancer patients experiencing pain a year or more after surgery.

      Poorly controlled postoperative pain has negative physiological and psychological
      consequences. Furthermore, effective acute pain control preserves immune function both by
      suppressing surgical stress response and decreasing the need for general anesthetics and
      opioids in the perioperative period.

      The ultrasound-guided modified, pectoral nerve block is a frequently used, easy, and reliable
      technique to provide complete analgesia during and after breast surgery. A major limitation
      to its use for postoperative analgesia is that the analgesic effect lasts only a few hours,
      after which moderate to severe pain at the surgical site may result in the need for
      alternative analgesic therapy. Several adjuvants have been used to prolong the analgesic
      duration of peripheral nerve block, including perineural/interfascial or intravenous
      dexamethasone.

      Our aim is to explore the efficacy of 8 mg dexamethasone added to US-guided modified pectoral
      nerve block on postoperative pain in patients undergoing major breast surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>morphine consumption in the first 72 hours</measure>
    <time_frame>72 hours</time_frame>
    <description>every participants receives a morphine pump (PCA) to exactly measure opioid-consumption</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS-scores in the first 72 hours</measure>
    <time_frame>72 hours</time_frame>
    <description>Every participant is being repeatedly asked to score pain intensity on the visual-analog scale (VAS). This is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points (0-10). VAS is the most common scale for pain quantification worldwide. A VAS-scale of 0 indicates &quot;no pain&quot; and 10 indicates &quot;worst pain imaginable&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Effect of Drugs</condition>
  <condition>Breast Pain</condition>
  <condition>Anesthesia, Local</condition>
  <arm_group>
    <arm_group_label>ropivacaine + dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml dexamethasone (8mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ropivacaine + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml placebo (NaCl 0,9%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>modified pectoralis block for breast surgery with ropivacaine combined with dexamethasone 8mg.</description>
    <arm_group_label>ropivacaine + dexamethasone</arm_group_label>
    <other_name>Dexabene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>modified pectoralis block for breast surgery with ropivacaine combined with placebo (NaCl 0,9%).</description>
    <arm_group_label>ropivacaine + placebo</arm_group_label>
    <other_name>sodium chloride (NaCl) 0,9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine Injection [Naropin]</intervention_name>
    <description>30ml (=60mg) for modified pectoralis block (thoracic regional fascial plane block)</description>
    <arm_group_label>ropivacaine + dexamethasone</arm_group_label>
    <arm_group_label>ropivacaine + placebo</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female gender

          -  a American Society of Anesthesiologists (ASA) score of 1 or 2

          -  weight: body mass index (BMI) 18 - 35 kg/m2

          -  informed consent

          -  elective, unilaterale breast surgery

        Exclusion Criteria:

          -  bleeding disorders

          -  any known allergy to the medication

          -  diabetes mellitus

          -  any disease that leads to alterations in the corticosteroid physiology

          -  drug-dependency

          -  BMI &lt;18 or &gt; 35

          -  systemic infections

          -  psychiatric diseases, that are associated with an alteration in the perception of pain

          -  tumor spread at the site of injection

          -  inflammation at the site of injection

          -  pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Lindner, Prof.Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Anesthesia and Intensive Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Hoerner, DDr</last_name>
    <phone>+43 512 504 83150</phone>
    <email>elisabeth.hoerner@tirol-kliniken.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guenther Putz, Prof.Dr.</last_name>
    <phone>+43 512 504 22400</phone>
    <email>guenther.putz@tirol-kliniken.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Hoerner, DDr.</last_name>
      <phone>+4351250483150</phone>
      <email>elisabeth.hoerner@tirol-klniken.at</email>
    </contact>
    <contact_backup>
      <last_name>Guenther Putz, AoUniv.Prof.</last_name>
      <phone>+4351250480275</phone>
      <email>guenther.putz@i-med.ac.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastodynia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

